Where does Edgewise Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$167.8M-25.4%	-$133.81M-33.6%	-$100.16M-48.1%	-$67.64M-58.0%
Depreciation and amortization	$2.04M-0.6%	$2.05M+38.7%	$1.48M+298%	$371K+20.5%
Stock-based compensation	$34.75M+40.6%	$24.71M+40.7%	$17.56M+60.7%	$10.92M+148%
Change in accounts payable	——	——	-$92K-296%	$47K—
Change in accrued liabilities	——	$4.36M+162%	$1.66M—	——
Change in other assets	$7.96M+342%	-$3.29M-193%	$3.55M—	——
Change in operating lease liabilities	-$748K—	——	——	$2.92M—
Net cash from operating activities	-$143.82M-31.9%	-$109.03M-18.6%	-$91.95M-74.7%	-$52.64M-57.1%
Capital expenditures	$256K-80.5%	$1.31M-77.2%	$5.75M+3.6%	$5.55M+730%
Proceeds from maturities/sales of investments	——	——	$344.38M—	——
Net cash from investing activities	——	——	$102.89M—	——
Proceeds from issuance of common stock	——	——	$52.62M-59.4%	$129.53M+115,550%
Payment of debt issuance costs	——	——	$165K—	——
Net cash from financing activities	$196.09M-21.3%	$249.25M+367%	$53.38M-58.9%	$129.94M-30.6%
Net increase (decrease) in cash	——	——	——	——
Accretion (Amortization) of Discounts and Premiums, Investments	$7.67M-38.9%	$12.55M+31.8%	$9.52M+1,653%	$543K—
Depreciation	$2.04M-0.6%	$2.05M+38.7%	$1.48M+298%	$371K+20.5%
Accrued compensation and employee benefits	——	$4.36M+162%	$1.66M—	——
Operating lease liabilities	-$748K—	——	——	$2.92M—
Accrued liabilities	$691K-40.3%	$1.16M—	——	$1.34M—
Increase (Decrease) in Prepaid Expense and Other Assets	$7.96M+342%	-$3.29M-193%	$3.55M—	——
Proceeds from maturities of investments	——	——	$20.12M—	——
Payments Of Debt Issuance Costs	——	——	$165K—	——
Accrued payables for capital expenditures	——	——	——	$2.58M—
Finance Lease Right Of Use Asset Amortization	$182K-17.6%	$221K+22.1%	$181K+6.5%	$170K—
Increase Decrease In Operating Lease Liability	-$748K—	——	——	$2.92M—
Deferred Offering Costs Included In Accounts Payable And Accrued Other Expenses	——	——	——	——
Free cash flow	-$144.07M-30.6%	-$110.34M-12.9%	-$97.69M-67.9%	-$58.18M-70.2%
Free cash flow	-$144.07M-30.6%	-$110.34M-12.9%	-$97.69M-67.9%	-$58.18M-70.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Edgewise Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.